These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12915097)

  • 1. Genetic control of HIV disease.
    Theodorou I; Capoulade C; Combadiere C; Debre P
    Trends Microbiol; 2003 Aug; 11(8):392-7. PubMed ID: 12915097
    [No Abstract]   [Full Text] [Related]  

  • 2. 25 years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines.
    Scherer E; Douek D; McMichael A
    Clin Exp Immunol; 2008 Oct; 154(1):6-14. PubMed ID: 18761662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts in HIV/AIDS.
    Martin D
    SADJ; 1999 Dec; 54(12):609-15. PubMed ID: 16892569
    [No Abstract]   [Full Text] [Related]  

  • 4. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure.
    Deeks SG
    JAMA; 2001 Jul; 286(2):224-6. PubMed ID: 11448286
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral pre-exposure prophylaxis: A new opportunity to slow HIV spread in India.
    Mayer KH; Chandhiok N; Thomas B
    Indian J Med Res; 2016 Feb; 143(2):125-8. PubMed ID: 27121509
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV/AIDS. Experts question danger of 'AIDS superbug'.
    Cohen J
    Science; 2005 Feb; 307(5713):1185. PubMed ID: 15731415
    [No Abstract]   [Full Text] [Related]  

  • 8. The clarifying role of time series data in the population genetics of HIV.
    Feder AF; Pennings PS; Petrov DA
    PLoS Genet; 2021 Jan; 17(1):e1009050. PubMed ID: 33444376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological recovery after 3 years' antiretroviral therapy in HIV-1-infected children.
    Resino S; Sanchez-Ramón S; Bellón JM; Correa R; Abad ML; Muñoz-Fernández MA
    AIDS; 2002 Feb; 16(3):483-6. PubMed ID: 11834962
    [No Abstract]   [Full Text] [Related]  

  • 10. Current HIV therapeutics: mechanistic and chemical determinants of toxicity.
    Chiao SK; Romero DL; Johnson DE
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):53-60. PubMed ID: 19152213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A problem of the HIV drug resistance].
    Nosik MN
    Vopr Virusol; 2014; 59(4):5-9. PubMed ID: 25549461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.
    Guérin S; Meyer L; Theodorou I; Boufassa F; Magierowska M; Goujard C; Rouzioux C; Debré P; Delfraissy JF;
    AIDS; 2000 Dec; 14(17):2788-90. PubMed ID: 11125899
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe HIV-associated thrombocytopenia despite effective highly active antiretroviral therapy in a vertically infected child.
    Ndagijimana JM; Kroll H; Niehues T
    AIDS; 2002 Mar; 16(5):802-3. PubMed ID: 11964543
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Simon VA;
    IAPAC Mon; 2001 Aug; 7(8):235-7. PubMed ID: 11708276
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance to antiretroviral drugs: a threat to the prevention and treatment of pediatric HIV infection.
    Krogstad PA
    J Infect Dis; 2007 May; 195(10):1393-5. PubMed ID: 17436216
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV treatment guidelines revised.
    Traynor K
    Am J Health Syst Pharm; 2010 Jan; 67(2):94. PubMed ID: 20065260
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV and drug resistance - interpretation and therapeutic progress.
    Gürtler L
    Intervirology; 2012; 55(2):77-8. PubMed ID: 22286873
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 19. The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
    Kozal MJ; Hullsiek KH; Macarthur RD; Berg-Wolf Mv; Peng G; Xiang Y; Baxter JD; Uy J; Telzak EE; Novak RM;
    HIV Clin Trials; 2007; 8(6):357-70. PubMed ID: 18042501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.